The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000471381p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
27/03/2026
Date registered
Help: Date registered
16/04/2026
Date last updated
Help: Date last updated
16/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Eggs for Healthy Aging: Optimising Nutrition in Older Adults
Scientific title
Effect of consumption of 2 eggs daily on nutritional status, physical function, and quality of life in older adults: a randomised controlled trial
Additional trial identifiers [1] 316061 0
None
Universal Trial Number (UTN)
Trial acronym
EGG-AGE
Related trial records

Health condition
Health condition(s) studied:
Malnutrition risk 339931 0
Condition category
Condition code
Diet and Nutrition 336161 336161 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This randomised controlled trial will evaluate the effectiveness of a 12-week intervention (2 eggs/day) on nutritional status, physical function, and quality of life among older adults living in retirement villages, with outcomes assessed at baseline (T1), week 6 (T2), week 12 (T3), and 6-month follow up (T4). The study will also identify practical strategies to support egg consumption in this population.

Participants will be randomised to one of two treatment arms; intervention or control. Intervention includes increased egg intake to 2 eggs per day, deemed a single serving of protein according to the Australian Guide to Healthy Eating. Control will continue with diet as normal. The intervention group will be provided with raw eggs to cook with along with recipes to the sum 2 eggs per day (14 eggs per week).

Adherence will be measured using self-reported dietary logs, returning of egg cartons and/or verbal confirmation of egg consumption during each delivery of eggs, as well as tracking of egg consumption through 3-day food records.
Intervention code [1] 332674 0
Lifestyle
Description of the comparator or control
The control arm of this trial will continue with their diet as normal along side general guide to healthy eating for malnutrition. They will be provided usual care as all will be identified as being at risk of, or having, malnutrition. Aiming not to change their egg intake over the 12-weeks they are in the trial. They will also complete the same assessments from baseline (T1) to 6-month follow up (T4). At the end of the 12-weeks, the control group will be provided the opportunity to receive the one months worth of eggs free of charge.

Usual care will be defined as being provided general guides on implementing a high-energy, high-protein based diet. Advise may include:
• Try consuming six smaller meals per day
• Include 3–4 extra serves of protein and energy-rich foods or drinks daily. Some examples include: 1) Extra serves of meat, baked beans, cheese; 2) Milk or soy-based drinks, eg milk shakes; 3) Extra desserts, eg ice cream, custard, cakes, biscuits; 4) Dried fruit, nuts, chocolate bars, chips 5) Fortify foods by adding milk powder, cream, butter
• Extra foods are consumed better if consumed between main meals
Control group
Active

Outcomes
Primary outcome [1] 343701 0
Nutrition Status
Timepoint [1] 343701 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3; primary end point), 6-month (final follow up; T4)
Secondary outcome [1] 455345 0
Quality of Life
Timepoint [1] 455345 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3), 6-month (final follow up; T4)
Secondary outcome [2] 455446 0
Nutrition status
Timepoint [2] 455446 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3), 6-month (final follow up; T4)
Secondary outcome [3] 455447 0
Physical function
Timepoint [3] 455447 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3), 6-month (final follow up; T4)
Secondary outcome [4] 455448 0
Physical function
Timepoint [4] 455448 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3), 6-month (final follow up; T4)
Secondary outcome [5] 455449 0
Physical function
Timepoint [5] 455449 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3), 6-month (final follow up; T4)
Secondary outcome [6] 455450 0
Physical function
Timepoint [6] 455450 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3), 6-month (final follow up; T4)
Secondary outcome [7] 455451 0
Physical function
Timepoint [7] 455451 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3), 6-month (final follow up; T4)
Secondary outcome [8] 459653 0
Nutrition status
Timepoint [8] 459653 0
Baseline (T1), 12-week (end-intervention; T3)
Secondary outcome [9] 459654 0
Egg Acceptability
Timepoint [9] 459654 0
Baseline (T1), 6-week (mid intervention; T2), 12-week (end-intervention; T3), 6-month (final follow up; T4)
Secondary outcome [10] 460106 0
Nutrition status
Timepoint [10] 460106 0
Baseline (T1), 12-week (end-intervention; T3)
Secondary outcome [11] 460114 0
Nutrition status
Timepoint [11] 460114 0
Baseline (T1), 12-week (end-intervention; T3)
Secondary outcome [12] 460118 0
Nutrition status
Timepoint [12] 460118 0
Baseline (T1), 12-week (end-intervention; T3)
Secondary outcome [13] 460121 0
Nutrition status
Timepoint [13] 460121 0
Baseline (T1), 12-week (end-intervention; T3)

Eligibility
Key inclusion criteria
Living in Victoria, Australia

Retirement living (i.e. lives in retirement villages, community dwelling, etc)

Aged 65 years or older

Currently living with malnutrition (MNA <17), or at risk of malnutrition (MNA 17-23.5) with self-reported weight loss or low-protein intake (<0.8g/kg) confirmed via 3-day food diary

Not intending to lose weight over the next 6 months

Willingness to complete dietary records via a computer or smart-phone or paper-based food-diary records

Understand and communicate in English

Willing to make dietary and/or behavioural changes in line if allocated to the intervention group for 12-weeks

Availability and willingness to attend all study visits and 6-month follow-up

Ability to provide informed consent
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Diagnosed egg allergy (IgE-mediated or clinician-diagnosed), including prior anaphylaxis to egg.

Any other documented severe adverse reactions to egg requiring medical treatment (even if not formally labelled “allergy”)

Familial hypercholesterolaemia (FH) (genetic or clinician diagnosed).

Moderate to severe chronic kidney disease (CKD) requiring dietary restriction of protein, phosphorus or potassium including dialysis-treated kidney disease, or clinician-diagnosed hyperphosphataemia.

Any unstable or clinically significant cardiometabolic condition that, in the opinion of the study doctor or investigator, would make participation unsafe or confound interpretation of outcomes, including:
- recent major myocardial infarction, stroke, coronary revascularisation, or hospitalisation for unstable heart failure within the past 6 months
- unstable angina or decompensated heart failure
- severe uncontrolled hypertension
- uncontrolled diabetes requiring acute treatment changes
- active medical advice to restrict egg intake or dietary cholesterol

Current immunosuppressive therapy, active immunosuppression, or history of solid organ transplant.

Unable to follow written and verbal instructions

Terminal illness with less than 6 months to live

Currently consuming greater than or equal to 6 eggs per week

Current enteral/parenteral feeding preventing whole-food intake

Immobile (eg chair or bed bound)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Randomisation will occur after participants have completed the baseline assessments and been provided a study ID. At the time of randomisation, the delegated study team member will press the “Randomise” button in the randomisation instrument in the participant's REDCap record. On pressing the button, the study team member will be alerted to which treatment arm the participant is allocated to. The study team will manually update the participants' group allocation with the following naming convention, EGG (for intervention) and CONT (for control) in REDcap as well as a study randomisation excel file containing all participants
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
At the time of randomisation, the delegated study team member will press the “Randomise” button in the randomisation instrument in the participant's REDCap record. On pressing the button, the study team member will be alerted to which treatment arm the participant is allocated to.
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 320660 0
Commercial sector/Industry
Name [1] 320660 0
Australian Eggs Limited
Country [1] 320660 0
Australia
Primary sponsor type
University
Name
University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 323291 0
None
Name [1] 323291 0
Address [1] 323291 0
Country [1] 323291 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 319200 0
University of Melbourne Central Human Research Ethics Committee
Ethics committee address [1] 319200 0
Ethics committee country [1] 319200 0
Australia
Date submitted for ethics approval [1] 319200 0
25/03/2026
Approval date [1] 319200 0
Ethics approval number [1] 319200 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 146582 0
A/Prof Jessica Biesiekierski
Address 146582 0
University of Melbourne, Food & Nutrition Building, Building 194 (room 305), Parkville VIC 3010
Country 146582 0
Australia
Phone 146582 0
+61 03 8344 0192
Fax 146582 0
Email 146582 0
Contact person for public queries
Name 146583 0
Jessica Biesiekierski
Address 146583 0
University of Melbourne, Food & Nutrition Building, Building 194 (room 305), Parkville VIC 3010
Country 146583 0
Australia
Phone 146583 0
+61 03 8344 0192
Fax 146583 0
Email 146583 0
Contact person for scientific queries
Name 146584 0
Jessica Biesiekierski
Address 146584 0
University of Melbourne, Food & Nutrition Building, Building 194 (room 305), Parkville VIC 3010
Country 146584 0
Australia
Phone 146584 0
+61 03 8344 0192
Fax 146584 0
Email 146584 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.